How to Get Evenity (Romosozumab) in New Jersey

What Evenity (Romosozumab) Is and Why It Matters for Severe Osteoporosis

Romosozumab, sold as Evenity, is a sclerostin-inhibiting monoclonal antibody that simultaneously increases bone formation and decreases bone resorption. The FDA approved it in April 2019 for postmenopausal women with osteoporosis at high or very high fracture risk. [1]

No other approved osteoporosis drug works through both arms of bone remodeling at the same time. That dual mechanism produces rapid gains in bone mineral density (BMD) that older agents cannot match in a 12-month window.

Clinical Evidence Behind the Approval

The ARCH trial (N=4,093, published NEJM 2017) compared romosozumab followed by alendronate against alendronate alone. At 24 months, the romosozumab-to-alendronate sequence reduced new vertebral fracture risk by 48% compared with alendronate alone (6.2% vs 11.9%, P<0.001). [2] Clinical non-vertebral fractures fell by 19% (P<0.04). [2]

The FRAME trial (N=7,180) showed that 12 months of romosozumab reduced vertebral fractures by 73% versus placebo at 12 months. [3] Lumbar spine BMD increased 13.3% from baseline. [3]

Who Qualifies Under FDA Labeling

FDA labeling restricts Evenity to postmenopausal women at high or very high fracture risk. [1] Clinically, prescribers use these criteria:

• T-score of -2.5 or below at lumbar spine or hip
• One or more prior fragility fractures, or T-score of -3.0 or below
• Intolerance or inadequate response to prior bisphosphonate therapy (common in the ARCH population)

The Endocrine Society's 2019 clinical practice guideline on osteoporosis recommends romosozumab as a first-line option in patients at very high fracture risk, defined as a recent fracture (within 12 months), T-score below -3.0, or FRAX 10-year major osteoporotic fracture probability above 30%. [4]

The Black-Box Cardiovascular Warning: What New Jersey Patients Must Know

Evenity carries an FDA black-box warning for increased risk of myocardial infarction (MI), stroke, and cardiovascular death. [1] In ARCH, cardiovascular serious adverse events occurred in 2.5% of romosozumab patients versus 1.9% of alendronate patients over 12 months. [2]

Who Should Not Receive Romosozumab

The FDA label contraindicates romosozumab in patients who have had an MI or stroke within the preceding 12 months. [1] New Jersey prescribers and telehealth clinicians are required to document a cardiovascular risk assessment before writing the prescription. Standard pre-treatment cardiac clearance includes a 12-lead ECG for patients with known coronary artery disease and a review of the past 12 months for cardiac events.

Shared Decision-Making Requirement

Because of the cardiovascular signal, the American Heart Association's 2023 cardiovascular-bone health joint statement advises that prescribers weigh fracture risk against cardiovascular risk explicitly in the clinical note. [5] Documenting this discussion is not just best practice in New Jersey. It directly supports prior authorization approval.

Step-by-Step: How to Get an Evenity Prescription in New Jersey

Getting romosozumab in New Jersey follows a defined sequence. Each step is manageable, but skipping one delays the entire process.

Step 1: Obtain a Current DXA Scan

A dual-energy X-ray absorptiometry (DXA) scan dated within 24 months is the starting point for every prior authorization in New Jersey. [6] If your last DXA is older than two years, you need a new scan before a prescriber can submit PA paperwork.

New Jersey has dozens of hospital-based and outpatient DXA centers. Many can schedule within one to two weeks. Bring prior DXA reports if available, because percent-change calculations from baseline strengthen the PA narrative.

Step 2: Calculate Your FRAX Score

FRAX is the WHO-endorsed fracture risk assessment tool. [7] Your prescriber enters your age, BMI, prior fractures, glucocorticoid use, rheumatoid arthritis status, parental hip fracture history, smoking, alcohol use, and femoral neck T-score to generate a 10-year probability for major osteoporotic fracture and hip fracture. Most New Jersey insurers require a FRAX printout in the PA packet.

Step 3: Order Pre-Treatment Laboratory Work

Four labs are mandatory before the first injection and must appear in the medical record:

• Serum calcium (hypocalcemia is a contraindication)
• 25-OH vitamin D (correct to above 20 ng/mL before starting)
• Serum creatinine / estimated GFR (dose adjustment guidance for severe renal impairment)
• CBC with differential (baseline immune status)

Some New Jersey insurers also request bone turnover markers, specifically serum procollagen type 1 N-terminal propeptide (P1NP) and C-terminal telopeptide (CTX), as part of the PA documentation. [8] Having these drawn at your initial visit prevents a second trip.

Step 4: See a Qualified Prescriber

In New Jersey, MDs, DOs, nurse practitioners (APNs), and physician assistants (PAs) are all legally authorized to prescribe romosozumab, provided they hold a current New Jersey controlled-substance certificate and an active DEA registration where required. APNs in New Jersey practice under a collaborative agreement with a physician for Schedule II-V substances but can prescribe non-scheduled drugs like romosozumab independently once their collaborative agreement is in place. [9]

Specialists who commonly prescribe Evenity in New Jersey include endocrinologists, rheumatologists, and orthopedic surgeons with a metabolic bone focus.

Step 5: Complete Prior Authorization

Every major New Jersey commercial plan (Horizon BCBSNJ, Aetna NJ, Cigna NJ, UnitedHealthcare NJ) requires PA for Evenity. NJ FamilyCare (Medicaid) covers romosozumab with PA for severe osteoporosis. [10]

A complete PA packet for New Jersey insurers typically includes:

• DXA results with T-scores
• FRAX printout
• Calcium and vitamin D lab values
• Documentation of prior osteoporosis therapy (bisphosphonate trial of at least 12 months, or documented intolerance)
• Cardiovascular risk assessment note
• ICD-10 code M81.0 (postmenopausal osteoporosis without current pathological fracture) or M80-series for fracture

Processing time is five to fifteen business days for standard review. Expedited review (72 hours) is available if the prescriber documents urgent fracture risk.

Step 6: Select a Specialty Pharmacy

Evenity is not stocked at most retail pharmacies. It ships through specialty pharmacy networks. Amgen's Evenity patient support program, called EVEN MORE Support, connects New Jersey patients with in-network specialty pharmacies and handles cold-chain shipping of the prefilled syringes. [11]

Once the specialty pharmacy receives a confirmed PA, standard delivery to a New Jersey address takes two to five business days. Injections must be refrigerated at 2 to 8 degrees Celsius.

Telehealth Options for Romosozumab in New Jersey

New Jersey permits telehealth prescribing for non-controlled medications, and romosozumab is not a controlled substance. [9] A New Jersey-licensed telehealth provider can evaluate your DXA, review labs, conduct a video or phone consultation, and transmit an Evenity prescription electronically to a specialty pharmacy.

What a Telehealth Visit Covers

A qualifying telehealth consultation for romosozumab in New Jersey must document the same elements as an in-person visit: fracture risk assessment, cardiovascular history, lab review, and a treatment plan that includes the 12-dose sequence and the post-romosozumab antiresorptive agent. [9] Telehealth prescribers cannot skip the cardiovascular risk discussion because the black-box warning applies regardless of visit modality.

HealthRX Telehealth Workflow in New Jersey

HealthRX's New Jersey telehealth workflow for romosozumab follows four stages: (1) upload existing DXA and labs through the secure patient portal before the visit; (2) complete a 30-minute video consultation with a board-certified clinician who reviews fracture risk, cardiovascular history, and goals of therapy; (3) receive an electronic PA submission within 24 hours of the visit if you meet criteria; (4) have your Evenity shipped cold-chain to your New Jersey address after PA approval. Patients who arrive with complete documentation (DXA, labs, prior medication records) shorten the overall timeline to as few as 10 business days from first contact.

Telehealth Limitations to Know

Telehealth prescribers cannot administer the injection. Evenity is given subcutaneously, and patients self-inject or visit a New Jersey-licensed infusion suite, primary care office, or rheumatology clinic for each of the 12 monthly doses. Most New Jersey patients self-administer after a brief injection training session, which can be delivered by a nurse or pharmacist in person or via video demonstration. [12]

Cost and Coverage: What New Jersey Patients Pay

Evenity's list price is approximately $1,825 per monthly dose (two 105 mg prefilled syringes), or roughly $21,900 for the full 12-dose course. [11] Out-of-pocket cost depends heavily on insurance.

Commercial Insurance in New Jersey

With an active PA and in-network specialty pharmacy, most New Jersey commercial plans cover Evenity at the specialty tier (typically 20 to 30% coinsurance after deductible). Amgen's co-pay assistance card can reduce out-of-pocket cost to as low as $0 per month for eligible commercially insured patients. [11]

NJ Medicaid (NJ FamilyCare)

NJ FamilyCare covers romosozumab for severe osteoporosis with prior authorization. [10] The PA criteria mirror commercial insurer requirements: documented T-score, fracture history or FRAX threshold, prior bisphosphonate trial, and cardiovascular clearance. Patients enrolled in NJ FamilyCare pay no copay once PA is approved.

Medicare Part D in New Jersey

Medicare Part D covers Evenity, but plan-specific formulary placement varies. Part D plans commonly place romosozumab on Tier 5 (specialty). The Extra Help program (Low Income Subsidy) can reduce the monthly cost to under $12 for qualifying New Jersey Medicare beneficiaries. [13]

What Happens After 12 Doses: Transitioning Therapy in New Jersey

Romosozumab is approved for exactly 12 monthly doses. [1] Stopping without transitioning to an antiresorptive agent causes rapid BMD loss. This is not a theoretical concern. The FRAME extension showed that patients who received placebo after romosozumab lost significant BMD within 12 months. [3]

Approved Transition Options

The two evidence-based transitions are:

• Denosumab (Prolia) 60 mg subcutaneous every 6 months. In the FRAME trial extension, switching to denosumab after romosozumab produced continued BMD gains of 9.4% at lumbar spine over 24 months of follow-up. [3]
• Alendronate 70 mg oral weekly. In ARCH, the romosozumab-to-alendronate sequence produced 48% relative risk reduction for vertebral fractures at 24 months. [2]

Your New Jersey prescriber should write the transition prescription before your 12th romosozumab dose, so there is no gap in therapy. A gap of even one month after denosumab discontinuation carries rebound fracture risk, and planning the handoff in advance prevents that scenario. [14]

Follow-Up DXA After Romosozumab

Most clinical guidelines and New Jersey insurer coverage policies require a follow-up DXA within 12 to 24 months after completing romosozumab to confirm BMD response and document continued medical necessity for antiresorptive therapy. [4] Schedule this scan before you finish your 12th injection.

503A Compounding Pharmacies in New Jersey: What Is Permitted

New Jersey-licensed 503A compounding pharmacies can prepare romosozumab formulations for individual patients under a valid prescription from a licensed New Jersey prescriber. [15] However, compounded romosozumab is not FDA-approved, and the clinical trials supporting Evenity's efficacy were conducted exclusively with the branded, manufacturer-produced product. [1]

The National Academies of Sciences, Engineering, and Medicine's 2023 report on pharmaceutical compounding noted that compounded versions of complex biologics like monoclonal antibodies present sterility and potency verification challenges not present in small-molecule compounding. [16] For that reason, most New Jersey bone specialists recommend branded Evenity through the specialty pharmacy network when insurance coverage is available, and reserve 503A compounding for patients with specific documented need (e.g., rare excipient allergy confirmed by allergist).

Transferring an Evenity Prescription to New Jersey

If you move to New Jersey or want to transfer care from an out-of-state provider, the process is straightforward provided your prior prescriber is licensed in a state with active telehealth reciprocity or you establish care with a New Jersey-licensed clinician.

A specialty pharmacy in New Jersey can receive a transferred Evenity prescription directly. The pharmacy will confirm the original PA is still active and that the remaining dose count (of the 12-dose series) is documented. If the original PA was issued by an out-of-state insurer and you have switched to a New Jersey plan, a new PA through the New Jersey plan is required before the pharmacy will dispense. [10] Bring all prior treatment records, including the original DXA, FRAX score, cardiovascular clearance note, and documentation of doses already received.